Drug Research
Caprion-HistoGeneX, Viroclinics-DDL Announce COVID-19 Research Partnership
Caprion-HistoGeneX and Viroclinics-DDL announced a new strategic partnership to expand their global capabilities addressing the emerging needs for therapeutic and prophylactic solutions to target infectious diseases including COVID-19. This partnership brings together the leadership of two contract research organizations...
Drug Research
Daiichi Sankyo and AstraZeneca Enter New Global Development and Commercialization Collaboration for Daiichi Sankyo’s ADC DS-1062
Daiichi Sankyo Company, Limited announced that it has entered into a global development and commercialization agreement with AstraZeneca for Daiichi Sankyo’s DS-1062, a TROP2 directed DXd antibody drug conjugate (ADC), currently in phase 1 clinical development for non-small cell...
Drug Research
Catalent Enters into Strategic Partnership with Editas Medicine to Support Gene Editing Medicine Pipeline
Editas Medicine, Inc., a leading genome editing company, and Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, announced that they have entered into...
Drug Research
Seven Indian Drugmakers Race To Develop Covid-19 Vaccine
Bharat Biotech, Serum Institute, Zydus Cadila, Panacea Biotec, Indian Immunologicals, Mynvax and Biological E among domestic pharma firms working on the vaccines in India
At least seven Indian pharma companies are working to develop a vaccine against coronavirus as they...
Drug Research
BioInvent’s BI-1206 could improve treatment in several cancers
Alexander Eggermont, MD, PhD, Chief Scientific Officer at the Princess Máxima Center and renowned expert in immunotherapy showcased the broad potential of BI-1206 in enhancing checkpoint inhibitors in solid cancers in a KOL event hosted by BioInvent on July...
Drug Research
Catalent Biologics to Invest $30 Million to Create European Clinical Manufacturing Center of Excellence in France
Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, announced that it plans to invest $30 million (€27 million) at its facility in Limoges,...
Drug Research
GSK and CureVac announce strategic mRNA technology collaboration
GlaxoSmithKline plc and CureVac announced the signing of a strategic collaboration agreement for the research, development, manufacturing and commercialisation of up to five mRNA-based vaccines and monoclonal antibodies (mAbs) targeting infectious disease pathogens. The collaboration complements GSK’s existing mRNA...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
